A tick panel is a blood test that checks for multiple tick-borne infections at once, rather than testing for each disease individually. It typically screens for the most common tick-borne illnesses in the United States: Lyme disease, ehrlichiosis, anaplasmosis, and babesiosis. Your doctor might order one if you develop unexplained fever, fatigue, headaches, or muscle pain after spending time in areas where ticks are common.
What a Tick Panel Tests For
A standard tick panel looks for antibodies your immune system produces in response to specific pathogens. The University of Michigan’s clinical lab panel, which is representative of what most hospitals offer, includes four targets: the bacterium that causes Lyme disease, Ehrlichia chaffeensis (the agent behind human monocytic ehrlichiosis), Anaplasma phagocytophilum (which causes anaplasmosis), and Babesia microti (a parasite that causes babesiosis). Some panels also include Rocky Mountain spotted fever, depending on the lab and the region where you live.
The reason these are bundled together is practical. Many of these infections produce overlapping symptoms: fever, fatigue, headache, and body aches. A single tick can even carry more than one pathogen, meaning you could be infected with two diseases from one bite. Rather than guessing which disease to test for, the panel casts a wider net.
How the Tests Actually Work
Tick panels use two main types of testing, and understanding the difference matters because it affects when each test is useful.
Antibody testing (serology) is the backbone of most tick panels. It measures your immune response rather than detecting the pathogen directly. For Lyme disease, the CDC recommends a two-step process: a screening test is run first, and if it comes back positive or borderline, a second, more specific test called a Western blot is used to confirm. The result is only considered positive when both steps are positive. For the other infections on the panel, a single antibody test with a specific threshold is typically sufficient.
PCR testing detects the actual genetic material of a pathogen in your blood. This is especially useful for ehrlichiosis and anaplasmosis, where the organisms circulate in the bloodstream during early infection. PCR can pick up an infection within the first two weeks of symptoms, a window when antibody tests often come back negative because your immune system hasn’t had time to mount a detectable response. The tradeoff is that PCR becomes less reliable once antibiotics have been started or once the acute phase passes.
Some panels use only serology, some combine PCR and serology, and some labs offer each approach separately. UNC Health’s tickborne illness panel, for example, includes both PCR for Ehrlichia and Anaplasma alongside antibody tests for the full set of pathogens.
Timing Changes Everything
The biggest limitation of a tick panel is the timing window. Antibody-based tests rely on your immune system producing enough antibodies to be detected, and that takes time. For Lyme disease specifically, antibody tests frequently come back falsely negative during the first few weeks after infection. The CDC notes that FDA-cleared tests reach good sensitivity only after four to six weeks have passed since infection.
This creates a frustrating gap. If you develop the classic bull’s-eye rash of Lyme disease (erythema migrans), your doctor will likely diagnose and treat you based on that alone, without waiting for blood work. The tick panel becomes most valuable when symptoms are ambiguous, when the rash never appeared, or when weeks have passed and you’re still feeling unwell.
For ehrlichiosis and anaplasmosis, PCR testing can fill this early gap since it detects the pathogen directly. This is why clinicians are advised to consider PCR specifically for patients with new-onset fever, headache, muscle pain, and fatigue, particularly if blood work shows a low white blood cell count, low platelets, or elevated liver enzymes.
Understanding Your Results
Tick panel results can be more nuanced than a simple positive or negative. The panel measures two types of antibodies, and each tells a different story.
IgM antibodies appear first, usually within one to two weeks of infection, and indicate a recent or active infection. IgG antibodies develop later and can persist for months or even years after the infection has resolved. A positive IgM with a negative IgG suggests early infection. A positive IgG alone may indicate a past infection that your body has already cleared, or it could reflect ongoing disease depending on your symptoms.
For Lyme disease, the CDC specifies that IgM testing is only meaningful within the first 30 days of symptoms. After that point, a positive IgM result is more likely to be a false positive and shouldn’t be used to make a diagnosis. The IgG Western blot becomes the more reliable indicator for infections lasting longer than a month, requiring at least 5 out of 10 specific protein markers to be present for a positive result.
A completely negative panel doesn’t always rule out tick-borne disease. If the test was drawn too early, before antibodies developed, a repeat test two to four weeks later may be needed. Your doctor will weigh the results against your symptoms, exposure history, and the time of year.
When a Tick Panel Is Ordered
Doctors don’t typically order a tick panel for every tick bite. Most tick bites don’t transmit disease, and in many cases a period of watchful waiting is appropriate. The panel is ordered when symptoms suggest a tick-borne illness is already developing.
Common reasons include unexplained fever with recent outdoor exposure, a rash that doesn’t clearly match erythema migrans, joint pain or swelling without another explanation, or neurological symptoms like facial drooping or severe headaches weeks after a known bite. Lab abnormalities like low platelet counts or elevated liver enzymes alongside these symptoms strengthen the case for ordering the full panel rather than a single disease test.
Geography plays a role too. In the northeastern and upper midwestern United States, where Lyme disease is most prevalent, doctors may have a lower threshold for ordering these tests. In the Southeast, ehrlichiosis and Rocky Mountain spotted fever are more common concerns, and the panel may be adjusted accordingly.
Limitations Worth Knowing
No tick panel catches everything. The standard panel covers the most common infections, but ticks in the U.S. transmit at least a dozen different diseases, including Powassan virus, tularemia, and alpha-gal syndrome, none of which appear on a routine panel. If your symptoms don’t match the usual suspects, your doctor may need to order additional specialized tests.
Antibody tests also can’t distinguish between an active infection and a past one that’s already resolved. In areas where tick-borne diseases are common, some people carry detectable antibodies from previous exposures without being currently sick. This is why results are always interpreted alongside your clinical picture, not in isolation.
Current diagnostic methods are also limited to testing for known pathogens. Newer approaches like metagenomic sequencing, which can identify any pathogen in a blood sample without needing to know what to look for, are being explored in research settings but remain too expensive and complex for routine clinical use.